

24 MAY 2021

Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada

Authors: Hannah Chung MPH¹, Siyi He MSc¹, Sharifa Nasreen PhD¹, Maria E. Sundaram PhD^{1,2}, Sarah A. Buchan PhD^{1,2,3,4}, Sarah E. Wilson MD MSc^{1,2,3,4}, Branson Chen MSc¹, Andrew Calzavara MSc¹, Deshayne B. Fell PhD^{1,5,6}, Peter C. Austin PhD^{1,7}, Kumanan Wilson MD MSc⁸, Kevin L. Schwartz MD MSc^{1,2,3}, Kevin A. Brown PhD^{1,2,3}, Jonathan B. Gubbay MD MSc³, Nicole E. Basta PhD⁹, Salaheddin M. Mahmud MD PhD¹⁰, Christiaan H. Righolt PhD¹⁰, Lawrence W. Svenson PhD^{11,12,13,14}, Shannon E. MacDonald PhD^{13,15}, Naveed Z. Janjua DrPH^{16,17}, Mina Tadrous PharmD PhD^{1,18}, and Jeffrey C. Kwong MD MSc^{1,2,3,4,19,20} on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators

Affiliations:

¹ ICES, Toronto, ON

² Dalla Lana School of Public Health, University of Toronto, Toronto, ON

³ Public Health Ontario, ON

⁴ Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON

⁵ School of Epidemiology and Public Health, University of Ottawa, ON

⁶ Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON

⁷ Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON

⁸ Department of Medicine, University of Ottawa, Ottawa and Bruyere Hospital Research

Institutes, Ottawa, ON

24 MAY 2021

⁹ Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montreal, QC

¹⁰ Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, MB

¹¹ Analytics and Performance Reporting Branch, Alberta Health, Edmonton, AB

¹² Division of Preventive Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB

¹³ School of Public Health, University of Alberta, Edmonton, AB

¹⁴ Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB

¹⁵ Faculty of Nursing, University of Alberta, Edmonton, AB

¹⁶ British Columbia Centre for Disease Control, Vancouver, BC

¹⁷ School of Population and Public Health, University of British Columbia, Vancouver, BC

¹⁸ Women's College Hospital, Toronto, ON

¹⁹ Department of Family and Community Medicine, University of Toronto, Toronto, ON

²⁰ University Health Network, Toronto, ON

Corresponding author:

Jeff Kwong

Senior Scientist, ICES

G1 06, 2075 Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5

jeff.kwong@utoronto.ca

Phone: (416) 480-4055 x1-7665

24 MAY 2021

47 Fax: (416) 480-6048

48

49 Abstract word count: 300

50 Manuscript word count: 2992

51 Tables/Figures: 5

52 References: 29

24 MAY 2021

ABSTRACT:

Objectives: To estimate the effectiveness of one and two doses of mRNA COVID-19 vaccines against symptomatic infection and severe outcomes.

Design: Using a test-negative design study and linked laboratory, vaccination, and health administrative databases, we estimated adjusted vaccine effectiveness (aVE) against symptomatic infection and severe outcomes (hospitalization or death) using multivariable logistic regression.

Setting: Ontario, Canada between 14 December 2020 and 19 April 2021.

Participants: Community-dwelling adults aged ≥ 16 years who were tested for SARS-CoV-2 and had COVID-19 symptoms.

Interventions: Pfizer-BioNTech's BNT162b2 or Moderna's mRNA-1273 vaccine.

Main outcome measures: Laboratory-confirmed SARS-CoV-2 identified by RT-PCR; hospitalization or death associated with SARS-CoV-2 infection.

Results: Among 324,033 symptomatic individuals, 53,270 (16.4%) were positive for SARS-CoV-2 and 21,272 (6.6%) received ≥ 1 vaccine dose. Among test-positive cases, 2,479 (4.7%) had a severe outcome. aVE against symptomatic infection ≥ 14 days after receiving only 1 dose was 60% (95%CI, 57 to 64%), increasing from 48% (95%CI, 41 to 54%) at 14–20 days after the first dose to 71% (95%CI, 63 to 78%) at 35–41 days. aVE ≥ 7 days after receiving 2 doses was 91% (95%CI, 89 to 93%). Against severe outcomes, aVE ≥ 14 days after receiving 1 dose was 70% (95%CI, 60 to 77%), increasing from 62% (95%CI, 44 to 75%) at 14–20 days to 91% (95%CI, 73 to 97%) at ≥ 35 days, whereas aVE ≥ 7 days after receiving 2 doses was 98% (95%CI, 88 to 100%). For adults aged ≥ 70 years, aVE estimates were lower after receiving 1 dose, but

24 MAY 2021

75 were comparable to younger adults after 28 days. After 2 doses, we observed high aVE against
76 E484K-positive variants.

77 **Conclusions:** Two doses of BNT162b2 and mRNA-1273 vaccines are highly effective against
78 both symptomatic infection and severe outcomes. Effectiveness is lower after only a single dose,
79 particularly for older adults shortly after the first dose.

24 MAY 2021

INTRODUCTION

Understanding how clinical trial efficacy estimates of COVID-19 vaccines translate into real-world effectiveness estimates is crucial, given differences in populations, dosing intervals, and emerging variants.¹ Due to COVID-19 vaccine supply constraints, Canada's National Advisory Committee on Immunization (NACI) recommended extending the interval between doses to a maximum of 16 weeks.² With vaccine supply constraints globally, determining the effectiveness of these vaccines following a single dose vs. two doses is important for informing policy for many countries.¹

We applied the test-negative design to linked, population-based health databases in Ontario, Canada (population 15 million) to evaluate vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection and severe outcomes (i.e., hospitalization or death associated with SARS-CoV-2 infection) for two mRNA vaccines (Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273).

METHODS

Study population, setting, and design

We conducted a test-negative design study among community-dwelling Ontarians who had symptoms consistent with COVID-19. The test-negative design is comparable to a nested case-control design, with symptomatic individuals who are tested for the presence of a pathogen of interest serving as the nesting cohort.^{1,3,4} All Ontarians aged ≥ 16 years, eligible for provincial health insurance, not living in long-term care, and who were tested for SARS-CoV-2 between 14 December 2020 and 19 April 2021 were eligible for inclusion. We excluded individuals who tested positive for SARS-CoV-2 prior to 14 December 2020 and recipients of the ChAdOx1

24 MAY 2021

vaccine. We restricted the analysis to individuals who were documented to have at least one relevant COVID-19 symptom at the time of testing.

Data sources and definitions

We linked data from provincial SARS-CoV-2 laboratory testing, COVID-19 vaccination, and health administrative datasets using unique encoded identifiers and analyzed them at ICES.

Outcomes

Our first primary outcome of interest was symptomatic SARS-CoV-2 infection, ascertained by real-time reverse transcription polymerase chain reaction (RT-PCR).⁵ Using data from the Ontario Laboratories Information System (OLIS), which captured 91.8% (n=258,207) of all provincially reported cases of laboratory-confirmed COVID-19 (n=281,261) during the study period, test-positive individuals were treated as cases and test-negative individuals were treated as controls. Since symptom onset dates were inconsistently reported in OLIS, we used the specimen collection date as the index date. For cases with multiple positive tests, we used the date of their first positive test. For controls with multiple negative tests, we used the date of a randomly selected negative test as the index date.

We obtained information on variants and mutations from the Public Health Case and Contact Management system (CCM), which contains information on the clinical course of cases and the results of screening tests for N501Y and E484K mutations and whole genome sequencing results that identify specific variant of concern (VOC) lineages (B.1.1.7, B.1.351, P.1). All RT-PCR-positive specimens with cycle threshold values ≤ 35 were tested for the N501Y mutation (starting

24 MAY 2021

3 February 2021) and the E484K mutation (starting 22 March 2021).⁶ We considered samples with positive N501Y and negative E484K mutations as lineage B.1.1.7, and samples with positive N501Y and E484K mutations as lineage B.1.351 or P.1. We combined the latter two lineages for our analysis because there were very small numbers of cases identified using whole genome sequencing.

Our second primary outcome was severe disease associated with SARS-CoV-2 infection, defined as either hospitalization or death with a recent positive test, using the earliest of the specimen collection date or the hospitalization or death date as the index date. We identified these outcomes using CCM (for both hospitalizations and deaths), the Canadian Institute for Health Information's Discharge Abstract Database (DAD; for hospitalizations), and the Ontario Registered Persons Database (RPDB; for deaths). For hospitalizations identified using DAD, a positive test must have occurred within 14 days prior to or 3 days after admission. For deaths identified using RPDB, a positive test must have occurred within 30 days prior to death or within 7 days post-mortem.

COVID-19 vaccination

BNT162b2 became available in Ontario on 14 December 2020, and mRNA-1273 on 28 December 2020.⁷ The initial vaccination phase prioritized high-risk populations such as older adults living in congregate settings, healthcare workers, adults living in Indigenous communities, and adults aged ≥ 80 years. Ontario had initially followed the manufacturers' recommended dosing schedules (i.e., a 21-day interval for BNT162b2 and a 28-day interval for mRNA-1273), but in late January 2021 extended the interval to 35-42 days for everyone except older adults

24 MAY 2021

living in congregate settings and Indigenous individuals, due to disruptions in vaccine supply. In early March, Ontario adopted NACI's recommendation to delay administration of the second dose by up to 16 weeks for most individuals.^{8,9} By April, eligibility was expanded to include adults in high COVID-19-incidence communities, individuals with certain health conditions and their caregivers, certain essential frontline workers, and graduated expansion of eligibility by decreasing age.⁷ As of 19 April 2021, 28% of Ontario adults had received at least one dose of a COVID-19 vaccine.¹⁰ Comprehensive documentation of all COVID-19 vaccination events in Ontario, including product, date of administration, and dose number, is recorded in COVaxON, a centralized COVID-19 vaccine information system.

Covariates

We obtained age, sex, and postal code of residence as of 14 December 2020 from RPDB. We obtained the number of RT-PCR tests for each subject during the 3 months prior to 14 December 2020 from OLIS to use as a proxy for highly tested individuals at increased risk of exposure to SARS-CoV-2 infection (e.g., healthcare workers and caregivers of long-term care residents, who must also undergo serial SARS-CoV-2 testing). We grouped testing dates into 2-week periods to capture temporal changes in viral activity and regional vaccine roll-out. We determined the presence of comorbidities that increase the risk of severe COVID-19,¹¹ identified from various databases using validated algorithms and commonly accepted diagnostic codes, which have been described elsewhere.¹² We ascertained receipt of influenza vaccination during the 2019/2020 and/or 2020/2021 influenza season using physician and pharmacist billing claims in the Ontario Health Insurance Plan and Ontario Drug Benefit databases, respectively. We determined the public health unit of residence using the postal code and Statistics Canada Postal Code

24 MAY 2021

Conversion File Plus (version 7B) and grouped them into larger regions. We obtained information at the ecologic level of dissemination area (DA) on four important social determinants of health (median neighbourhood income, proportion of the working population employed as non-health essential workers [i.e., those unable to work from home], average number of persons per dwelling, and proportion of the population who self-identify as a visible minority) from 2016 Census data.¹³ DAs generally contain 400-700 individuals. Details related to these covariates are available in **Supplementary Table S1**.

Statistical analysis

We conducted descriptive analyses and calculated standardized differences to compare characteristics between test-positive cases and test-negative controls, and between vaccinated and unvaccinated individuals.

We used multivariable logistic regression models to estimate the odds ratio (OR) comparing the odds of vaccination between test-positive cases and test-negative controls. We estimated unadjusted and adjusted odds ratios accounting for all covariates listed above. These covariates were selected *a priori* based on their known associations with SARS-CoV-2 infection or severity and COVID-19 vaccine receipt.^{2,11,14} VE was calculated using the following formula: $VE = (1 - OR) \times 100\%$.

For the primary analysis, we estimated overall VE (for both vaccines combined) for those who received only 1 dose by their index date and those who received 2 doses by their index date. We considered index dates within varying intervals after vaccination.

24 MAY 2021

We also estimated VE ≥ 14 days after the first dose (among those who only received 1 dose) and ≥ 7 days after the second dose, stratified by vaccine product (BNT162b2 or mRNA-1273), age group (16–39, 40–69, and ≥ 70 years), sex, presence of any comorbidity, epidemic wave (index dates 14 December 2020–7 February 2021, representing wave 2 in Ontario; 8 February 2021–21 March 2021, representing the period between wave 2 and wave 3; and 22 March 2021–19 April 2021, representing wave 3), and variant (earlier variant vs. B.1.1.7 vs. B.1.351 or P.1). We also estimated VE by varying intervals after vaccination stratified by age group.

We repeated these analyses for severe outcomes, with adjustments to the intervals after vaccination due to reduced sample sizes.

All analyses were conducted using SAS Version 9.4 (SAS Institute Inc., Cary, NC). All tests were two-sided and used $p < 0.05$ as the level of statistical significance.

RESULTS

From 14 December 2020 – 19 April 2021, 2,171,449 individuals were tested for SARS-CoV-2. After excluding individuals who had SARS-CoV-2 infection prior to the study period and individuals who had received ChAdOx1 vaccine, 60.5% of those remaining did not have symptoms consistent with COVID-19 or had no symptom information recorded in OLIS, 24.4% were recorded as asymptomatic, and 15.1% had symptoms consistent with COVID-19 recorded at the time of testing (**eFigure 1**). Grouped together, individuals with COVID-19-like symptoms and those deemed asymptomatic had similar characteristics as the remaining individuals, except

24 MAY 2021

for COVID-19 vaccine uptake, public health unit region, and number of previous SARS-CoV-2 tests (**eTable 2**). Of the 324,033 symptomatic tested individuals, 53,270 (16.4%) tested positive for SARS-CoV-2 and 21,272 (6.6%) had received ≥ 1 dose of mRNA vaccine. Among test-positive cases, 2,479 (4.7%) were hospitalized or died.

Test-positive cases were more likely to be male; more likely to reside in Peel Region or Toronto; more likely to have had zero SARS-CoV-2 tests during the 3 months prior to the vaccination program; less likely to have received an influenza vaccine; and more likely to reside in neighbourhoods with lower income, more persons per dwelling, and greater proportions of essential workers and visible minorities (**Table 1**). Vaccinated individuals were older; less likely to be male; more likely to have had multiple SARS-CoV-2 tests during the 3 months prior to the vaccination program; more likely to have a comorbidity; and more likely to have received an influenza vaccine. Compared to recipients of mRNA-1273 vaccine, recipients of BNT162b2 vaccine were younger, more likely to be female, and less likely to have a comorbidity (**eTable 3**). Most individuals (77% for BNT162b2, 76% for mRNA-1273) had received only 1 dose by the index date.

Against symptomatic infection, adjusted VE (aVE) ≥ 14 days after receiving only 1 dose was 60% (95%CI, 57–64%). This increased from 48% (95%CI, 41–54%) at 14–20 days to a plateau of 71% (95%CI, 63–78%) at 35–41 days (**Figure 1, eTable 4**). We observed a 16% increase in risk of symptomatic infection 7–13 days after a first dose (aVE -16%; 95%CI, -26% to -6%). aVE ≥ 7 days after receiving 2 doses was 91% (95%CI, 89–93%). Against severe outcomes of hospitalization or death, aVE ≥ 14 days after receiving 1 dose was 70% (95%CI, 60–77%),

24 MAY 2021

increasing from 62% (95%CI, 44–75%) at 14–20 days to 91% (95%CI, 73–97%) at ≥ 35 days, whereas aVE ≥ 7 days after receiving 2 doses was 98% (95%CI, 88–100%) (**Figure 2, eTable 4**).

In subgroup analyses of VE against symptomatic infection, we observed higher aVE ≥ 14 days after receiving only 1 dose with mRNA-1273 than BNT162b2, for younger adults than adults aged ≥ 70 years, for individuals with no comorbidities than for those with comorbidities, and against the earlier variant and B.1.1.7 than B.1.351 or P.1 (though 95% confidence intervals for aVE for variants overlapped) (**Figure 3a, eTable 5**). However, aVE estimates ≥ 7 days after receiving 2 doses were high (all $\geq 88\%$) and comparable across all subgroups, including against E484K-positive variants. Against severe outcomes, we observed higher aVE ≥ 14 days after receiving 1 dose for younger adults aged 16–39 years, but aVE estimates ≥ 0 days after receiving 2 doses were mostly similar across subgroups (**Figure 3b, eTable 6**).

Among adults ≥ 70 years, VE against symptomatic infection after 1 dose increased to 64% (95%CI 46–76%) at 28–34 days and 85% (95%CI 38–97%) at 42–48 days, whereas comparable VE estimates were achieved sooner after 1 dose for younger adults (**Figure 4, eTable 7**). For older adults, VE against severe outcomes was comparable at ≥ 35 days after 1 dose (93%; 95%CI, 71–98%) as after receiving 2 doses (97%; 95%CI, 86–99%).

DISCUSSION

We estimated very high ($>90\%$) vaccine effectiveness of mRNA vaccines BNT162b2 and mRNA-1273 against symptomatic SARS-CoV-2 infection with full vaccination (i.e., ≥ 7 days after receipt of a second dose), and moderate ($\sim 50\text{--}70\%$) VE with partial vaccination (i.e., ≥ 14

24 MAY 2021

days after receipt of only a first dose). Estimates for both full and partial vaccination were approximately 10% higher against hospitalization or death, and VE increased over time after a first dose. In subgroup analyses, we observed lower VE against symptomatic infection after a first dose for recipients of BNT162b2, adults aged ≥ 70 years, and individuals with comorbidities. However, VE was consistently high across subgroups for fully vaccinated individuals, and also for older adults after longer intervals following receipt of a first dose. We also noted a slightly increased risk of symptomatic infection on days 7-13 after a first dose, compared to no vaccination.

Our findings for fully vaccinated individuals are comparable with clinical trial efficacy estimates and other real-world effectiveness estimates reported in a range of settings.¹⁵⁻²⁵ Existing evidence estimating one-dose effectiveness from observational studies is heterogeneous,^{20,22,24-26} with estimates for symptomatic infection ranging from 57% (95%CI, 50–63%)²² to 72% (95%CI, 58–86%)²⁵ and post-hoc calculations from efficacy trials approximately 90%.^{27,28} There is similar heterogeneity among one-dose effectiveness estimates in older adults,^{18,26,29} with estimates generally lower for older adults after the first dose,^{22,26} and increasing with time. Our analysis identified an effectiveness against symptomatic infection of 63% (95%CI, 40–72%) ≥ 49 days after only the first dose, in keeping with several other studies reporting one-dose effectiveness.^{22,24} Our analysis also reflects extant evidence that effectiveness increases to very high levels after the second dose, including in older adults.²² Our finding that receipt of 2 doses of mRNA vaccines was not associated with appreciable vaccine escape by lineage B.1.1.7 or E484K-positive variants (i.e., B.1.351 and P.1) is notable.

24 MAY 2021

The increased risk of infection 7-13 days after receiving the vaccine could be due to an increase in SARS-CoV-2 exposures shortly prior to, during, or after vaccination. Individuals may be incubating at the time of vaccination, they may be exposed due to inadequate infection prevention and control measures at (or when travelling to/from) vaccination clinics, or they may assume protection immediately following vaccination and engage in higher risk behaviours before a sufficient immune response has developed. Future studies should evaluate the effectiveness of infection prevention and control measures in vaccination clinics and examine the potential role of behavioural changes post first dose of COVID-19 vaccines.

Our study had some limitations. First, our study sample was limited to those with COVID-19 symptoms recorded in OLIS. Not all laboratories in Ontario currently have the information technology infrastructure to submit symptom information recorded on the SARS-CoV-2 laboratory requisition into OLIS. Thus, the generalizability of our findings to the broader population is uncertain. In addition, COVID-19 vaccination status is now collected on the laboratory requisition. This may introduce selection bias and underestimate the true VE estimate if symptoms were more likely to be documented on requisition forms for vaccinated individuals who ultimately test positive for SARS-CoV-2, for example. Traditional test-negative design studies collect vaccination status among all individuals with symptoms consistent with the pathogen under study, to minimize this selection bias. However, the congruence of our findings for fully vaccinated individuals with extant studies provides some reassurance that any under- or overestimation of VE is likely to be small. Second, because symptom onset date is largely unavailable in OLIS and CCM only has information on test-positive cases, we used specimen collection date as the index date. This may have led to classifying some individuals into an

24 MAY 2021

incorrect dose-to-index date interval, because their symptom onset would have been several days prior to getting tested, leading to underestimation of VE during earlier intervals. Furthermore, we could not limit the study population to individuals tested within 10 days of symptom onset, a commonly used inclusion criterion for test-negative studies. Prolonging the interval between symptom onset and testing increases the likelihood of false-negative cases, which lowers VE estimates. However, 89% of cases with both symptom onset and specimen collection date documented in CCM (not the source of symptom data for this study) were tested within 10 days of symptom onset. Third, our results may have been impacted by outcome misclassification of severe outcomes due to unlinked case records and incomplete capture of severe outcomes in CCM, and delays in identifying hospitalizations in DAD (which are dependent on individuals being discharged) and deaths in RPDB. Fourth, some of our covariates may be subject to measurement error. We used frequency of previous SARS-CoV-2 tests as a proxy to identify individuals at higher risk of exposure (and increased likelihood to be targeted for early vaccination). However, we did not include point-of-care tests because they are incompletely captured in OLIS. Furthermore, since access to testing is variable, we might not have adequately controlled for this concept. Finally, we may not have adequately accounted for confounding bias with the covariates that were available in the study databases.

Our findings suggest that older individuals and those with comorbidities may benefit from risk-based recommendations to minimize second-dose delays. However, rising protection against severe outcomes – arguably the more important outcome – with increasing time after a first dose provides support for delaying the second dose. Mathematical modelling could be conducted to demonstrate how, particularly for jurisdictions with limited vaccine supply, vaccines should be

24 MAY 2021

distributed to maximize population protection (e.g., the relative benefits of providing second doses earlier to older populations versus providing more first doses to younger populations who respond better to a single dose and leading to more rapid achievement of herd immunity by maximizing coverage with 1 dose). Since VE against symptomatic infection after 1 dose is only moderate, and among older adults appears to be modest even at 14–20 days, individuals need to be informed that besides the absence of benefit during the first 2 weeks (and likely longer for older adults) after a first dose, they should continue to adhere to recommended public health measures, such as mask-wearing, physical distancing, and avoidance of social gatherings.

Conflicts of interest

KW is CEO of CANImmunize and serves on the data safety board for the Medicago COVID-19 vaccine trial. SMM has received unrestricted research grants from Merck, GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Roche-Assurex for unrelated studies. SMM has received fees as an advisory board member for GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, and Seqirus. CHR has received an unrestricted research grant from Pfizer for an unrelated study. The other authors declare no conflicts of interest.

Contributors

HC and JCK designed and oversaw the study. SH and HC obtained the data and conducted all analyses (data set and variable creation and statistical modelling). BC contributed to data analyses and data preparation for the symptomatic data set. SN, MES, HC, and JCK drafted the manuscript. All authors contributed to the analysis plan, interpreted the results, critically

24 MAY 2021

reviewed and edited the manuscript, approved the final version, and agreed to be accountable for all aspects of the work.

Ethics approval

ICES is a prescribed entity under Ontario's Personal Health Information Protection Act (PHIPA). Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of the data in this project is authorized under section 45 and approved by ICES' Privacy and Legal Office.

Funding

This work was supported by the Canadian Immunization Research Network (CIRN) through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944). This project was also supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH). JCK is supported by Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine. PCA is supported by a Mid-Career Investigator Award from the Heart and Stroke Foundation.

Data availability statement

24 MAY 2021

The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

Acknowledgments

We would like to acknowledge Public Health Ontario for access to case-level data from CCM and COVID-19 laboratory data, as well as assistance with data interpretation. We also thank the staff of Ontario's public health units who are responsible for COVID-19 case and contact management and data collection within CCM. We thank IQVIA Solutions Canada Inc. for use of their Drug Information Database. The authors are grateful to the Ontario residents without whom this research would be impossible.

Disclaimers

This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). This study was supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontario's ongoing response to COVID-19 and its related impacts. The study sponsors did not participate in the design and conduct of the study; collection, management, analysis and

24 MAY 2021

402 interpretation of the data; preparation, review or approval of the manuscript; or the decision to
 403 submit the manuscript for publication. Parts of this material are based on data and/or information
 404 compiled and provided by the Canadian Institute for Health Information (CIHI) and by Cancer
 405 Care Ontario (CCO). However, the analyses, conclusions, opinions and statement expressed
 406 herein are solely those of the authors, and do not reflect those of the funding or data sources; no
 407 endorsement by ICES, MOH, MLTC, OHDP, its partners, the Province of Ontario, CIHI or CCO
 408 is intended or should be inferred.

409

24 MAY 2021

References

1. Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines. *JAMA*. 2020.
2. National Advisory Committee on Immunization. Guidance on the prioritization of key populations for COVID-19 immunization. <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-prioritization-key-populations-covid-19-vaccination.html>. Published 2021. Updated February 12, 2021. Accessed May 2, 2021.
3. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine*. 2013;31(17):2165-2168.
4. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. *American journal of epidemiology*. 2016;184(5):345-353.
5. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. *BMJ*. 2020;369:m1808.
6. Updates to PHO's Variants of Concern Laboratory Testing. Public Health Ontario. <https://www.publichealthontario.ca/en/about/blog/2021/lab-voc-testing-updates>. Published 2021. Updated March 25, 2021. Accessed May 3, 2021.
7. Ontario's COVID-19 vaccination plan. Ontario Ministry of Health. <https://covid-19.ontario.ca/ontarios-covid-19-vaccination-plan#our-three-phased-vaccination-plan>. Published 2021. Updated April 30, 2021. Accessed May 3, 2021.
8. *Vaccine Clinical Advisory Group (VCAG) Recommendations on Exceptions to Extended Dose Intervals for COVID-19 Vaccines*. Ontario: Ontario Ministry of Health; March 26, 2021.
9. *Extension of the Second Dose Interval*. Ontario: Ontario Ministry of Health; Updated April 23, 2021.
10. ICES COVID-19 Dashboard. ICES. <https://www.ices.on.ca/DAS/AHRQ/COVID-19-Dashboard>. Published 2021. Accessed May 3, 2021.
11. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. US Centers for Disease Control and Prevention. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>. Published 2021. Updated April 30, 2021. Accessed May 3, 2021.
12. Kwong JC, Buchan SA, Chung H, et al. Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort. *Vaccine*. 2019;37(31):4392-4400.
13. Statistics Canada/Statistique Canada. Dictionary, Census of Population, 2016. <https://www12.statcan.gc.ca/census-recensement/2016/ref/dict/geo021-eng.cfm>. Published 2020. Accessed October 13, 2020.
14. Sundaram ME, Calzavara A, Mishra S, et al. Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study. *CMAJ*. 2021.
15. Vahidy FS, Pischel L, Tano ME, et al. Real world effectiveness of COVID-19 mRNA vaccines against hospitalizations and deaths in the United States. *medRxiv*. 2021.

24 MAY 2021

16. Mason T, Whitston M, Hodgson J, et al. Effects of BNT162b2 mRNA vaccine on Covid-19 infection and hospitalisation among older people: matched case control study for England. *medRxiv*. 2021.
17. Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population — first results from a cohort study in Southern Sweden. *medRxiv*. 2021.
18. Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. *medRxiv*. 2021.
19. Pawlowski C, Lenehan P, Puranik A, et al. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. *medRxiv*. 2021.
20. Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel using aggregated counts. *medRxiv*. 2021.
21. Yelin I, Katz R, Herzel E, et al. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities. *medRxiv*. 2021.
22. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *The New England journal of medicine*. 2021.
23. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people. *SSRN (pre-print server)*. 2021.
24. Andrejko K, Pry J, Myers JF, et al. Early evidence of COVID-19 vaccine effectiveness within the general population of California. *medRxiv*. 2021.
25. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *The Lancet*. 2021;397(10286):1725-1735.
26. Chodick G, Tene L, Patalon T, et al. The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. *medRxiv*. 2021.
27. Skowronski DM, De Serres G. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine: Letter to the Editor. *The New England journal of medicine*. 2021;384(16):1576-1577.
28. Annex A: Report to JCVI on estimated efficacy of a single dose of Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a single dose of ChAdOx1 vaccine (AZD1222). UK: Public Health England; December 22 2020.
29. Hyams C, Marlow R, Maseko Z, et al. Assessing the effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination in prevention of hospitalisations in elderly and frail adults: a single centre test negative case-control study. *SSRN (pre-print server)*. 2021.

Table 1. Characteristics of symptomatic individuals tested for SARS-CoV-2 between 14 December 2020 and 19 April 2021 in Ontario, Canada.

Characteristic	SARS-CoV-2- positive, n (%) ^a (N=53,270)	SARS-CoV-2- negative, n (%) ^a (N=270,763)	Standardized difference ^b	Vaccinated with ≥1 dose of mRNA COVID-19 vaccine, n (%) ^a (N=21,272)	Unvaccinated, n (%) ^a (N=302,761)	Standardized difference ^b
Received ≥1 dose of COVID-19 vaccine	2,050 (3.8)	19,222 (7.1)	-	-	-	-
Received 2 doses of COVID-19 vaccine	73 (0.1)	4,821 (1.8)	-	-	-	-
Tested positive for SARS-CoV-2	-	-	-	2,050 (9.6)	51,220 (16.9)	-
Earlier variant	-	-	-	579 (2.7)	27,510 (9.1)	-
B.1.1.7	-	-	-	807 (3.8)	12,282 (4.1)	-
B.1.351 or P.1 (E484K+ variants)	-	-	-	98 (0.5)	1,291 (0.4)	-
Age (years), mean (standard deviation)	42.4 (17.1)	43.2 (17.8)	0.04	51.8 (20.8)	42.4 (17.3)	0.49
Age group (years)						
16–29	15,175 (28.5)	72,238 (26.7)	0.04	3,457 (16.3)	83,956 (27.7)	0.28
30–39	10,024 (18.8)	59,326 (21.9)	0.08	4,011 (18.9)	65,339 (21.6)	0.07
40–49	9,642 (18.1)	46,225 (17.1)	0.03	3,287 (15.5)	52,580 (17.4)	0.05
50–59	9,460 (17.8)	40,874 (15.1)	0.07	3,112 (14.6)	47,222 (15.6)	0.03
60–69	5,279 (9.9)	27,342 (10.1)	0.01	2,261 (10.6)	30,360 (10.0)	0.02
70–79	2,426 (4.6)	14,888 (5.5)	0.04	2,272 (10.7)	15,042 (5.0)	0.21
≥80	1,264 (2.4)	9,870 (3.6)	0.07	2,872 (13.5)	8,262 (2.7)	0.40
Male sex	25,993 (48.8)	112,501 (41.5)	0.15	6,013 (28.3)	132,481 (43.8)	0.33
Public health unit region ^c						
Central East	2,624 (4.9)	29,194 (10.8)	0.22	1,969 (9.3)	29,849 (9.9)	0.02
Central West	8,322 (15.6)	48,419 (17.9)	0.06	3,853 (18.1)	52,888 (17.5)	0.02
Durham	1,433 (2.7)	8,583 (3.2)	0.03	522 (2.5)	9,494 (3.1)	0.04
Eastern	689 (1.3)	15,147 (5.6)	0.24	1,087 (5.1)	14,749 (4.9)	0.01
North	1,753 (3.3)	31,321 (11.6)	0.32	2,251 (10.6)	30,823 (10.2)	0.01
Ottawa	417 (0.8)	3,144 (1.2)	0.04	446 (2.1)	3,115 (1.0)	0.09
Peel	13,515 (25.4)	32,981 (12.2)	0.34	2,395 (11.3)	44,101 (14.6)	0.10
South West	7,562 (14.2)	39,316 (14.5)	0.01	3,885 (18.3)	42,993 (14.2)	0.11
Toronto	12,458 (23.4)	45,540 (16.8)	0.16	3,462 (16.3)	54,536 (18.0)	0.05
York	4,278 (8.0)	15,995 (5.9)	0.08	1,323 (6.2)	18,950 (6.3)	0.00
Biweekly period of test						
14 Dec 2020 to 27 Dec 2020	4,139 (7.8)	27,456 (10.1)	0.08	13 (0.1)	31,582 (10.4)	0.48
28 Dec 2020 to 10 Jan 2021	6,870 (12.9)	26,993 (10.0)	0.09	335 (1.6)	33,528 (11.1)	0.40

Characteristic	SARS-CoV-2- positive, n (%) ^a (N=53,270)	SARS-CoV-2- negative, n (%) ^a (N=270,763)	Standardized difference ^b	Vaccinated with ≥1 dose of mRNA COVID-19 vaccine, n (%) ^a (N=21,272)	Unvaccinated, n (%) ^a (N=302,761)	Standardized difference ^b
11 Jan 2021 to 24 Jan 2021	4,864 (9.1)	26,747 (9.9)	0.03	1,068 (5.0)	30,543 (10.1)	0.19
25 Jan 2021 to 7 Feb 2021	3,539 (6.6)	24,276 (9.0)	0.09	1,204 (5.7)	26,611 (8.8)	0.12
8 Feb 2021 to 21 Feb 2021	3,595 (6.7)	24,800 (9.2)	0.09	1,031 (4.8)	27,364 (9.0)	0.17
22 Feb 2021 to 7 Mar 2021	3,539 (6.6)	30,760 (11.4)	0.17	1,491 (7.0)	32,808 (10.8)	0.13
8 Mar 2021 to 21 Mar 2021	5,134 (9.6)	32,776 (12.1)	0.08	2,790 (13.1)	35,120 (11.6)	0.05
22 Mar 2021 to 4 Apr 2021	8,338 (15.7)	35,910 (13.3)	0.07	4,814 (22.6)	39,434 (13.0)	0.25
5 Apr 2021 to 19 Apr 2021	13,252 (24.9)	41,045 (15.2)	0.24	8,526 (40.1)	45,771 (15.1)	0.58
Number of tests in previous 3 months						
0	43,713 (82.1)	189,786 (70.1)	0.28	11,588 (54.5)	221,911 (73.3)	0.40
1	7,151 (13.4)	54,827 (20.2)	0.18	4,338 (20.4)	57,640 (19.0)	0.03
≥2	2,406 (4.5)	26,150 (9.7)	0.20	5,346 (25.1)	23,210 (7.7)	0.49
Any comorbidity ^d	23,212 (43.6)	127,974 (47.3)	0.07	12,218 (57.4)	138,968 (45.9)	0.23
Receipt of 2019-2020 and/or 2020-2021 influenza vaccination	13,751 (25.8)	89,395 (33.0)	0.16	9,587 (45.1)	93,559 (30.9)	0.30
Neighbourhood income quintile ^{c, e}						
1 (lowest)	11,878 (22.3)	47,944 (17.7)	0.11	3,750 (17.6)	56,072 (18.5)	0.02
2	11,154 (20.9)	51,470 (19.0)	0.05	4,146 (19.5)	58,478 (19.3)	0.00
3	11,477 (21.5)	52,628 (19.4)	0.05	4,233 (19.9)	59,872 (19.8)	0.00
4	10,146 (19.0)	56,676 (20.9)	0.05	4,513 (21.2)	62,309 (20.6)	0.02
5 (highest)	8,359 (15.7)	60,774 (22.4)	0.17	4,540 (21.3)	64,593 (21.3)	0.00
Essential workers quintile ^{c, f}						
1 (0%–32.5%)	6,440 (12.1)	50,664 (18.7)	0.18	3,917 (18.4)	53,187 (17.6)	0.02
2 (32.5%–42.3%)	11,225 (21.1)	60,040 (22.2)	0.03	4,664 (21.9)	66,601 (22.0)	0.00
3 (42.3%–49.8%)	11,106 (20.8)	56,108 (20.7)	0.00	4,468 (21.0)	62,746 (20.7)	0.01
4 (50.0%–57.5%)	11,576 (21.7)	52,849 (19.5)	0.05	4,211 (19.8)	60,214 (19.9)	0.00
5 (57.5%–100%)	12,519 (23.5)	49,067 (18.1)	0.13	3,859 (18.1)	57,727 (19.1)	0.02
Persons per dwelling quintile ^{c, g}						
1 (0–2.1)	5,781 (10.9)	51,852 (19.2)	0.23	4,277 (20.1)	53,356 (17.6)	0.06
2 (2.2–2.4)	6,641 (12.5)	52,326 (19.3)	0.19	4,219 (19.8)	54,748 (18.1)	0.04
3 (2.5–2.6)	5,633 (10.6)	37,229 (13.7)	0.10	3,020 (14.2)	39,842 (13.2)	0.03
4 (2.7–3.0)	12,967 (24.3)	63,774 (23.6)	0.02	4,874 (22.9)	71,867 (23.7)	0.02

Characteristic	SARS-CoV-2- positive, n (%) ^a (N=53,270)	SARS-CoV-2- negative, n (%) ^a (N=270,763)	Standardized difference ^b	Vaccinated with ≥1 dose of mRNA COVID-19 vaccine, n (%) ^a (N=21,272)	Unvaccinated, n (%) ^a (N=302,761)	Standardized difference ^b
5 (3.1–5.7)	21,833 (41.0)	63,459 (23.4)	0.38	4,709 (22.1)	80,583 (26.6)	0.10
Self-identified visible minority quintile ^{c, h}						
1 (0.0%–2.2%)	4,437 (8.3)	51,919 (19.2)	0.32	4,133 (19.4)	52,223 (17.2)	0.06
2 (2.2%–7.5%)	5,752 (10.8)	55,124 (20.4)	0.27	4,592 (21.6)	56,284 (18.6)	0.07
3 (7.5%–18.7%)	7,223 (13.6)	51,122 (18.9)	0.14	3,982 (18.7)	54,363 (18.0)	0.02
4 (18.7%–43.5%)	10,718 (20.1)	53,691 (19.8)	0.01	3,974 (18.7)	60,435 (20.0)	0.03
5 (43.5%–100%)	24,736 (46.4)	56,876 (21.0)	0.56	4,438 (20.9)	77,174 (25.5)	0.11

^aProportion reported, unless stated otherwise.

^bStandardized differences of >0.10 are considered clinically relevant.

^cThe sum of counts does not equal the column total because of individuals with missing information (<1.0%) for this characteristic.

^dComorbidities include chronic respiratory diseases, chronic heart diseases, hypertension, diabetes, immunocompromising conditions due to underlying diseases or therapy, autoimmune diseases, chronic kidney disease, advanced liver disease, dementia/frailty and history of stroke or transient ischemic attack.


^eNeighbourhood income quintile has variable cut-off values in each city/Census area to account for cost of living. A dissemination area (DA) being in quintile 1 means it is among the lowest 20% of DAs in its city by income.

^fPercentage of people in the area working in the following occupations: sales and service occupations; trades, transport and equipment operators and related occupations; natural resources, agriculture, and related production occupations; and occupations in manufacturing and utilities. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

^gRange of persons per dwelling.


^hPercentage of people in the area who self-identified as a visible minority. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

Figure 1. Unadjusted (panel A) and adjusted* (panel B) vaccine effectiveness estimates of COVID-19 mRNA vaccines (BNT162b2, mRNA-1273) against laboratory-confirmed symptomatic SARS-CoV-2 infection by various intervals, between 14 December 2020 and 19 April 2021 in Ontario, Canada.




* Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income, essential worker, persons per dwelling, proportion of persons employed as non-health essential workers and self-identified visible minority quintiles.

Figure 2. Unadjusted (panel A) and adjusted* (panel B) vaccine effectiveness estimates of COVID-19 mRNA vaccines (BNT162b2, mRNA-1273) against severe outcomes (hospitalization or death) associated with laboratory-confirmed symptomatic SARS-CoV-2 infection by various intervals, between 14 December 2020 and 19 April 2021 in Ontario, Canada.



* Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income, essential worker, persons per dwelling, proportion of persons employed as non-health essential workers and self-identified visible minority quintiles.

Figure 3. Adjusted* vaccine effectiveness estimates ≥ 14 days after Dose 1 (for individuals who received only 1 dose) and ≥ 0 days after Dose 2 by various factors, including vaccine product, patient characteristics, epidemic wave, and SARS-CoV-2 lineage against laboratory-confirmed symptomatic SARS-CoV-2 infection (panel A) and severe outcomes (hospitalization or death) (panel B) between 14 December 2020 and 19 April 2021.



* Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income, essential worker, persons per dwelling, proportion of persons employed as non-health essential workers and self-identified visible minority quintiles (unless adjusted variable was used for stratification).

□ For subgroup analyses by characteristic and SARS-CoV-2 lineage, individuals vaccinated with either mRNA vaccine was included.

**For vaccine effectiveness against symptomatic SARS-CoV-2 infection (panel A), this interval was ≥ 7 days after Dose 2. However, against serious outcomes (panel B), an alternative interval was selected (≥ 0 days after Dose 2) because of limited number of outcomes.

Figure 4. Adjusted* vaccine effectiveness estimates ≥ 14 days after Dose 1 and ≥ 0 days after Dose 2 in community-dwelling adults in Ontario, Canada against laboratory-confirmed symptomatic SARS-CoV-2 infection for adults aged ≥ 70 years (panel A), 40-69 years (panel B), and 16-39 years (panel C) and severe outcomes (hospitalization or death) for adults aged ≥ 70 years (panel D) and 40-69 years (panel E), between 14 December 2020 and 19 April 2021.

CONFIDENTIAL - DO NOT DISTRIBUTE

* Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income, essential worker, persons per dwelling, proportion of persons employed as non-health essential workers and self-identified visible minority quintiles (unless adjusted variable was used for stratification).

□ For subgroup analyses by characteristic and SARS-CoV-2 lineage, individuals vaccinated with either mRNA vaccine was included.

**For vaccine effectiveness against symptomatic SARS-CoV-2 infection (panels A, B, and C), this interval was ≥ 7 days after Dose 2. However, against serious outcomes (panels D and E), an alternative interval was selected (≥ 0 days after Dose 2) because of limited number of outcomes.

